Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results